Main menu

NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Ghent, Belgium-based Biogazelle said that it will primarily use the investment to further develop its research on therapeutic RNA targets for specific cancer types and expand its commercial activities.